VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations·BOSTON, MA·FY end 12/31·CIK 875320

Named Executive Officers

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Reshma KewalramaniCEO and President	$1.6M	$15.0M	—	$4.1M	$423.4K	$21.1M
Stuart A. ArbuckleFormer EVP & Chief Operating Officer	$521.5K	$9.3M	—	—	$132.9K	$10.0M
Charles F. WagnerJr.	$974.8K	$5.3M	—	$2.0M	$51.2K	$8.2M
Nia TatsisEVP & Chief Regulatory and Quality Officer	$750.0K	$4.9M	—	$1.3M	$42.2K	$7.0M
Amit Sachdev	$700.0K	$4.9M	—	$1.2M	$21.3K	$6.8M
Carmen Bozic	$835.0K	$4.4M	—	$1.4M	$57.5K	$6.6M

Reshma Kewalramani · FY 2025

Stock awards$15.0M71%

Performance bonus$4.1M19%

Salary$1.6M8%

Other$423.4K2%

TSR % vs. CEO comp actually paid · 5 fiscal years · Item 402(v) disclosure

TSR

CEO comp

FY21

-7%

$18M

FY22

+22%

$30M

FY23

+72%

$44M

FY24

+70%

$44M

FY25

+92%

$38M

Need at least two fiscal years of proxy data to draw the trend line. The ingestion worker will populate prior-year proxies as it processes them.